Oric Pharmaceuticals (ORIC) Stock Statistics & Valuation Metrics

Oric Pharmaceuticals has a market cap or net worth of $1.39B. The enterprise value is $1.34B.

Oric Pharmaceuticals has 100,358,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oric Pharmaceuticals’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -36.30%.

The current PE Ratio of Oric Pharmaceuticals is ―. Oric Pharmaceuticals’s PEG ratio is 0.28.

In the last 12 months, Oric Pharmaceuticals had revenue of 0.00 and earned -129.47M in profits. Earnings per share was -1.47.

In the last 12 months, operating cash flow was -111.21M and capital expenditures -872.00K, giving a free cash flow of -112.08M billion.

Oric Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Oric Pharmaceuticals upcoming earnings date is May 11, 2026, After Close (Confirmed).

Oric Pharmaceuticals as a current ratio of 14.13, with Debt / Equity ratio of 3.01%

In the past 12 months, Oric Pharmaceuticals has paid 0.00 in taxes.

Oric Pharmaceuticals EV to EBITDA ratio is -5.33, with an EV/FCF ratio of -6.00.

Oric Pharmaceuticals has $281.49M in cash and marketable securities with $11.55M in debt, giving a net cash position of $269.94M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Oric Pharmaceuticals is $20.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy